These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25100108)

  • 21. [Novelties in the treatment of heart failure].
    Souček F; Novak J
    Vnitr Lek; 2017; 63(4):255-264. PubMed ID: 28520449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations for the clinical use of cardiac natriuretic peptides.
    Emdin M; Clerico A; Clemenza F; Galvani M; Latini R; Masson S; Mulè P; Panteghini M; Valle R; Zaninotto M; Ganau A; Mariotti R; Volpe M; Aspromonte N; Cacciatore G; Cappelletti P; L'Abbate A; Miglio F; Ottani F; Pagani F; Passino C; Plebani M; Sarzani R; Zucchelli G; ; ; ; ; ;
    Ital Heart J; 2005 May; 6(5):430-46. PubMed ID: 15934421
    [No Abstract]   [Full Text] [Related]  

  • 23. B-type natriuretic peptide in heart failure.
    Moe GW
    Curr Opin Cardiol; 2006 May; 21(3):208-14. PubMed ID: 16601459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serial measurements of high sensitive cardiac troponin I in patients with acutely decompensated heart failure treated with carperitide or nitrates.
    Sato Y; Nishi K; Saijo S; Tanada Y; Goto T; Takahashi N; Yamamoto E; Fukuhara R; Miyamoto T; Taniguchi R; Fujiwara H; Takatsu Y
    J Cardiol; 2010 Jul; 56(1):66-72. PubMed ID: 20381318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B-type natriuretic peptides in management of acute decompensated heart failure.
    Yancy CW
    Heart Fail Clin; 2006 Jul; 2(3):353-64. PubMed ID: 17386904
    [No Abstract]   [Full Text] [Related]  

  • 26. Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failure.
    Saltzberg MT
    Rev Cardiovasc Med; 2004; 5 Suppl 4():S17-27. PubMed ID: 15627915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nesiritide in acute heart failure.
    de Moraes Barros GD; de Carvalho Leite CR
    Lancet; 2003 Sep; 362(9388):999. PubMed ID: 14511941
    [No Abstract]   [Full Text] [Related]  

  • 28. Nesiritide--not verified.
    Schreiner G
    N Engl J Med; 2005 Oct; 353(14):1525-7; author reply 1525-7. PubMed ID: 16211709
    [No Abstract]   [Full Text] [Related]  

  • 29. Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF).
    Ezekowitz JA; Hernandez AF; Starling RC; Yancy CW; Massie B; Hill JA; Krum H; Diaz R; Ponikowski P; Metra M; Howlett JG; Gennevois D; O'Connor CM; Califf RM; Fonarow GC
    Am Heart J; 2009 Feb; 157(2):219-28. PubMed ID: 19185628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agents with vasodilator properties in acute heart failure.
    Singh A; Laribi S; Teerlink JR; Mebazaa A
    Eur Heart J; 2017 Feb; 38(5):317-325. PubMed ID: 28201723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance.
    Abassi Z; Karram T; Ellaham S; Winaver J; Hoffman A
    Pharmacol Ther; 2004 Jun; 102(3):223-41. PubMed ID: 15246247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted biological therapies reach the heart: the case of serelaxin for heart failure.
    Kumar VA; Wilson SS; Ayaz SI; Levy PD
    Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nesiritide: the latest drug for treating heart failure.
    Fontana D
    Crit Care Nurse; 2006 Feb; 26(1):39-44, 46-7. PubMed ID: 16443809
    [No Abstract]   [Full Text] [Related]  

  • 34. New therapeutic choices in the management of acute congestive heart failure.
    Young JB
    Rev Cardiovasc Med; 2001; 2 Suppl 2():S19-24. PubMed ID: 12439358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New and emerging drug therapies for the management of acute heart failure.
    Krum H; Liew D
    Intern Med J; 2003 Nov; 33(11):515-20. PubMed ID: 14656255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The development of new medical treatments for acute decompensated heart failure.
    Teerlink JR
    Heart Fail Monit; 2002; 2(4):129-37. PubMed ID: 12634887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B-type natriuretic peptide in cardiovascular disease.
    de Lemos JA; McGuire DK; Drazner MH
    Lancet; 2003 Jul; 362(9380):316-22. PubMed ID: 12892964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic therapies for acutely decompensated heart failure.
    Fonarow GC
    Rev Cardiovasc Med; 2002; 3 Suppl 4():S18-27. PubMed ID: 12439427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute decompensated heart failure: best evidence and current practice.
    Mehta R; Feldman D
    Minerva Cardioangiol; 2005 Dec; 53(6):537-47. PubMed ID: 16333237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
    Teerlink JR
    Am Heart J; 2003 Feb; 145(2 Suppl):S26-33. PubMed ID: 12594449
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.